Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Array Biopharma Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is handled by 1 distinct examiner in 1 distinct art unit. CHAO, ALLEN is the busiest examiner, with 1 pending matter, so the available activity is concentrated in one prosecution channel.
The immediate strategy can remain application-specific, with attention to the pending claims and the technical evidence supporting them. Counsel can use the single examiner and art-unit assignment to prepare a focused response and assess whether an interview would clarify the examiner’s concerns. Portfolio-wide coordination is still relevant for consistent biotechnology terminology, but the data does not show multiple examination groups requiring separate routing.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHAO, ALLEN | 1 | 73.3% | +28.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18709091 | CRYSTALLINE FORM OF N-(2-CHLORO-3-((5-CHLORO-3-METHYL-4-OXO-3,4-DIHYDROQUINAZOLIN-6-YL)AMINO)-4-FLUOROPHENYL)-3-FLUOROAZETIDINE-1-SULFONAMIDE | CHAO, ALLEN | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18709091 | CRYSTALLINE FORM OF N-(2-CHLORO-3-((5-CHLORO-3-METHYL-4-OXO-3,4-DIHYDROQUINAZOLIN-6-YL)AMINO)-4-FLUOROPHENYL)-3-FLUOROAZETIDINE-1-SULFONAMIDE | CHAO, ALLEN | 1622 | §112 | Non-Final OA | — | Pending | May 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialArray Biopharma Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Allen Chao has the most, with 1 of Array Biopharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.